DAIGAKU

This brand name is authorized in Hong Kong SAR China.

Active ingredients

The drug DAIGAKU contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII U6F3787206 - AMINOCAPROIC ACID
 

Aminocaproic acid is 6-aminohexanoic acid, which acts as an inhibitor of fibrinolysis. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity.

 
Read more about Aminocaproic acid
2
UNII V1Q0O9OJ9Z - CHLORPHENIRAMINE MALEATE
 

Chlorphenamine is a potent antihistamine (H1-antagonist). Antihistamines diminish or abolish the actions of histamine in the body by competitive reversible blockade of histamine H1-receptor sites on tissues. Chlorphenamine also has anticholinergic activity.

 
Read more about Chlorphenamine
3
UNII MZ1131787D - NAPHAZOLINE HYDROCHLORIDE
 

Naphazoline is a sympathomimetic amine with pronounced alpha adrenergic activity and as a consequence has vasoconstrictor activity.

 
Read more about Naphazoline
4
UNII 89DS0H96TB - ZINC SULFATE, UNSPECIFIED FORM
 

Zinc sulfate is a source of zinc which is an essential trace element and involved in a number of body enzyme systems. Severe deficiency causes skin lesion, alopecia, diarrhoea, increased susceptibility to infections and failure to thrive in children.

 
Read more about Zinc sulfate

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
HK Department of Health Drug Office 42060

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.